A new study reveals declines in prostate cancer screening and diagnoses in the United States in recent years, as well as decreases in the use of definitive treatments in men who have been diagnosed.
Twenty five years after it opened for enrollment, the landmark Prostate Cancer Prevention Trial has delivered a final verdict. Finasteride, a common hormone-blocking drug, reduces mens' risk of getting prostate cancer without increasing their risk of dying from the disease.
A multi-center study that validates the clinical performance of IsoPSA -- a new blood test that has proven to be more accurate in predicting overall risk of prostate cancer than standard prostate-specific antigen (PSA) -- will be presented during the AUA Annual Meeting this weekend in San Francisco. Results suggest that use of IsoPSA may substantially reduce the need for biopsy, and may thus lower the likelihood of overdetection and overtreatment of nonlethal prostate cancer.
A software tool to automatically calculate how extensively bones have been infiltrated by prostate cancer is both accurate and speedy, capturing key prognostic information related to survival and the development of symptoms over time.
Researchers have identified a compound that blocks the spread of pancreatic and other cancers in various animal models. When cancer spreads from one part of the body to another in a process called metastasis, it can eventually grow beyond the reach of effective therapies. Now, there is a new plan of attack against this deadly process, thanks to scientists at the National Institutes of Health, Northwestern University and their collaborative research partners.
Scientists have developed a new compound that inhibits the spread of cancer cells, which is what makes the disease so lethal. The compound, metarrestin, significantly reduced metastasis by human prostate, pancreatic and breast cancer transplanted into mice. Mice treated with it had fewer metastatic tumors and lived longer than mice that did not receive treatment. Metarrestin is being submitted to the FDA as an investigational drug.
Researchers at the University of Cincinnati have found that MRI fusion biopsy -- coupling MRI and ultrasound to visualize suspicious lesions in the prostate gland and targeting the biopsy to that particular area -- outperformed standard prostate biopsy in patients with a prior negative prostate biopsy.
Increasing numbers of male veterans are opting out of immediate surgery or radiation to treat low-risk prostate cancer, postponing treatment unless the cancer worsen.
University of Alberta scientists have taken a critical step towards supplying Alberta's demand for medical isotopes. Their newly published findings could have major implications for other health jurisdictions across North America as well. Researchers at the university's Medical Isotope and Cyclotron Facility used a particle accelerator known as a cyclotron to produce enough isotopes for up to 1,000 diagnostic procedures in a day.
The technique makes use of tiny, three-dimensional ball-like aggregates of cells called spheroids.